entinostat has been researched along with Germinoblastoma in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic variables revealed dose-dependent and dose-proportional increases." | 2.73 | A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. ( Coffin, D; Eckhardt, SG; Gore, L; McCoy, C; O'Bryant, CL; Rothenberg, ML; Sandler, AB; Scholz, C; Schott, A; Schultz, MK, 2008) |
| "The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275." | 2.71 | Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. ( Acharya, M; Chung, EJ; Elsayed, Y; Figg, WD; Headlee, D; Hwang, K; Kalnitskiy, M; Melillo, G; Monga, M; Murgo, A; Ryan, QC; Sausville, EA; Sparreboom, A; Trepel, JB; Ye, J; Zwiebel, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, TCS | 1 |
| Chan, AHY | 1 |
| Ganesan, A | 1 |
| Gore, L | 1 |
| Rothenberg, ML | 1 |
| O'Bryant, CL | 1 |
| Schultz, MK | 1 |
| Sandler, AB | 1 |
| Coffin, D | 1 |
| McCoy, C | 1 |
| Schott, A | 1 |
| Scholz, C | 1 |
| Eckhardt, SG | 1 |
| Ryan, QC | 1 |
| Headlee, D | 1 |
| Acharya, M | 1 |
| Sparreboom, A | 1 |
| Trepel, JB | 1 |
| Ye, J | 1 |
| Figg, WD | 1 |
| Hwang, K | 1 |
| Chung, EJ | 1 |
| Murgo, A | 1 |
| Melillo, G | 1 |
| Elsayed, Y | 1 |
| Monga, M | 1 |
| Kalnitskiy, M | 1 |
| Zwiebel, J | 1 |
| Sausville, EA | 1 |
| Rasheed, W | 1 |
| Bishton, M | 1 |
| Johnstone, RW | 1 |
| Prince, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Closed by Sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for entinostat and Germinoblastoma
| Article | Year |
|---|---|
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
Topics: Anilides; Biological Products; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Histone Dea | 2020 |
Histone deacetylase inhibitors in lymphoma and solid malignancies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Depsipep | 2008 |
2 trials available for entinostat and Germinoblastoma
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Enzyme Inhib | 2008 |
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Topics: Administration, Oral; Adult; Aged; Benzamides; Drug Administration Schedule; Enzyme Inhibitors; Fema | 2005 |